KFG
BEAM icon

Kingdom Financial Group’s Beam Therapeutics BEAM Stock Holding History

Kingdom Financial Group’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27 Hold
1
– – ﹤0.01% 813
2026
Q1 		$18 Hold
1
– – ﹤0.01% 830
2025
Q4 		$21 Buy
+1
New +$26 ﹤0.01% 719

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Kingdom Financial Group's BEAM Position: Q2 2026 in Review

Kingdom Financial Group held its Beam Therapeutics (BEAM) position steady in Q2 2026 at 1 share worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #813.

Kingdom Financial Group first reported a position in BEAM in Q4 2025 and has held it in 3 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Kingdom Financial Group held 1 share of Beam Therapeutics worth $27 as of Q2 2026.
  • Kingdom Financial Group left its Beam Therapeutics share count unchanged in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of Kingdom Financial Group's portfolio in Q2 2026, its #813 holding.
  • Kingdom Financial Group first reported a position in Beam Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Kingdom Financial Group's 13F filing for Q2 2026, filed 7 Aug 2026.